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companies. METHODS: We identified branded antidepressant and antipsychotic
launches between 2003 and 2010. Market authorisation dates and P&R dates were
sourced from national databases and launch dates were determined using IMS
MIDAS data. The average time between market authorisation, P&R and launch was
then calculated for fifteen European countries. RESULTS: In most countries the
identified products were not launched until P&R was secured, making it a signifi-
cant barrier to patient access. The average time taken to achieve P&R was approx-
imately 310 days, with significant variation between countries. This delay was
frequently longer than the average P&R delay seen across all therapy areas. On
average only the UK, Germany and Denmark achieved P&R within Transparency
Directive guidelines. Significant delays were seen in Portugal and France, taking on
average 550 and 610 days respectively to gain P&R. CONCLUSIONS: In addition to
known development challenges for CNS products, manufacturers experience
greater delays in securing P&R in Europe, denying patients timely access to these
drugs. Few countries comply with the current Transparency Directive[2], and if
proposed changes are implemented to reduce the delay to 120 days, even fewer will
be compliant. P&R is an additional hurdle to access that particularly impacts CNS
drugs, and stronger efforts to reduce these delays are needed.
DU4
INAPPROPRIATE USE OF DRUGS INFLUENCES HEALTH BUDGET OF POPULATION
Sabo A, Tomic Z, Calasan J, Milijasevic B, Vukmirovic S
Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia and Montenegro
OBJECTIVES: Recently, there is growing evidence of inappropriate variation in use
of certain medicines. In Serbia the consumption of pentoxifylline, dihydroergotox-
ine, nicergoline, deproteinized calf blood extract (DCBE) and cinnarizine, drugs
with uncertain clinical benefit (UCB drugs), with clinical trials with little evidence
suggesting their clinical benefit, is unusually high. The aim of this study was to
analyze the consumption of UCB drugs in second largest city in Serbia – Novi Sad,
in 1984 and 2008., to compare with those in entire Serbia, Denmark and Norway,
and to examine the potential impact on population budget. METHODS: The study
included data on consumption of these medicines in 1984. and 2008., in Novi Sad.
Data were obtained from all state-owned and private pharmacies on the territory of
Novi Sad. The number of (DDD/1000 inh/day) was calculated using ATC/DDD
methodology. RESULTS: Total consumption of analyzed drugs with uncertain clin-
ical benefit in Novi Sad has surprisingly increased in 2008 (12,59DDD/TID) in com-
parison to 1984 (7.37DDD/TID). Also, their total consumption in entire Serbia in
2008. was higher than in Novi Sad (16,72DDD/TID) and even several dozens of times
higher than in Denmark and Norway (0.2DDD/TID). The money which population
spent for UCB drugs yearly was more than 90 Mill EU in Serbia Although different
administrative and educational approaches were applied in Serbia, their use not
only did not decrease, but has significantly increased throughout years.
CONCLUSIONS: These results suggest the need for putting greater efforts into ed-
ucation of general population who buys the UCB medicines in high amounts on
their own accord. The work is part of SerbianSP No41012.
PODIUM SESSION III:
DRIVERS OF REIMBURSEMENT TECHNOLOGY
RE1
FACTORS INFLUENCING DRUG REIMBURSEMENT DECISION IN SCOTLAND
Charokopou M, Heeg B, Majer IM
Pharmerit International, Rotterdam, Zuid-Holland, The Netherlands
OBJECTIVES: A reimbursement prediction model was previously developed based
on a dataset of submissions to the Scottish Medicines Consortium (SMC) between
2008 and 2010. The aim was to update and re-analyze the dataset, and to test
internal and external validity of the prediction model on submissions from 2011
and 2012. METHODS: A database of submissions between January 2005 and March
2012 was created. Data of 405 applications were collected, including information on
the reimbursement decision (yes/no), clinical data and indicators of the health
economic model quality supporting the submission. The impact of these variables
was estimated with univariate and multivariate logistic regression models. The
multivariate model was identified by a backward selection procedure. Internal
validity was assessed by the area under the receiver operating characteristic (ROC)
curve. External validity was conducted and judged by a classification test to predict
the SMC decision based on 2011-2012 data. RESULTS: Out of 405 applications 226
received positive recommendation (56%) and 131 (58%) of them were reimbursed
with restriction, e.g. limited patient population or restricted time period. Based on
univariate analyses, three factors had the largest significant effect on the reim-
bursement: poor pharmacoeconomic analysis design (OR0.03), high ICER
(OR0.16) and unclear/ inferior efficacy outcomes (OR0.25). The final multivariate
model included the following further factors: antineoplastic-immunomodulating
agent (OR0.47), combination therapy (OR2.00), biological drug (OR0.16), place-
bo-uncontrolled trial (OR0.50), extended indication (OR4.24), innovative drug
(OR2.07). The area under the ROC curve was high; 87.7%. Based on the external
validation, using a model estimated on data until December 2010 and a cut-off
point of 50%, 79.8% of the predicted reimbursement decisions in 2011-2012 were
correctly classified. CONCLUSIONS: The new prediction model demonstrates in-
ternal and external validity for 2011-2012. Therefore, the model could be used as
input when further optimizing the market access strategy for products in clinical
development.
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A DETAILED COMPARISON OF DUTCH AND SWEDISH DRUG REIMBURSEMENT
DECISIONS: WHAT EVIDENCE IS AVAILABLE, WHICH CRITERIA ARE USED, AND
IS THE DECISION-MAKING PROCESS TRANSPARENT?
Franken MG1, Nilsson F2, Sandmann F1, de Boer A3, Koopmanschap MA1
1Erasmus University, Rotterdam, The Netherlands, 2Dental and Pharmaceutical Benefits Agency,
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OBJECTIVES: To compare Dutch and Swedish drug reimbursement decisions and
to investigate the available evidence, used criteria, outcomes and transparency of
the decision-making process.METHODS:We investigated Dutch and Swedish pub-
licly available drug reimbursement dossiers from 2005 until July 2011. Applications
and outcomes were compared and classified into different categories. For dossiers
that included a full pharmacoeconomic evaluation (i.e. cost-effectiveness and/ or
cost-utility analysis) in both countries, we compared in detail how the available
evidence was assessed to appraise societal value. RESULTS: Pharmacoeconomic
evaluations were more often available in Swedish dossiers due to many exemp-
tions in The Netherlands (mainly orphan and HIV drugs). Reimbursement dossiers
only provided a full economic evaluation in both countries for eleven drugs. The
reimbursement decision differed for four drugs, in which relatively more restric-
tions were observed. Although Dutch dossiers provided more details, all dossiers
included information of underlying clinical and economic studies. Comparators
were always reported. Using a similar comparator (8x) resulted in a similar (5x) and
a different (3x) therapeutic value judgement, while a different comparator (3x)
resulted twice in a similar judgement. Swedish ‘yes’ decisions (10x) were judged
cost-effective; ‘no’ decisions (two for one drug) were judged cost-ineffective. Dutch
‘yes’ decisions (9x, including two second decisions) were evaluated sufficiently (3x),
reasonably (1x), moderately (2x), and insufficiently (3x) founded pharmacoeco-
nomic evidence; all ‘no’ decisions (4x) were insufficiently founded. Appraisal ele-
ments were descriptively reported. The (high) severity of the disease was explicitly
mentioned in three overlapping cases. However, the actual influence of disease
severity on the final ‘yes’ decision remained unclear. CONCLUSIONS: Both coun-
tries make their reimbursement reports publicly available. Although the assess-
ment is reasonable transparent, both countries could improve transparency of the
appraisal process by more explicitly showing the actual role of each different (so-
cietal) criterion in drug reimbursement decision making.
RE3
HOW WILL THE NEW NHS CHANGES IN ENGLAND IMPACT THE
IMPLEMENTATION OF RISK-SHARING SCHEMES FOR ONCOLOGY TREATMENTS?
Jeffery M, Assimakopoulos M, White R
Access Partnership, London, UK
OBJECTIVES: With the current English NHS reforms will the new Clinical Commis-
sioning Groups (CCGs) follow an Italian type regional approach to enable patient
access to innovative and premium priced medicines when implementing patient
access schemes. METHODS: We reviewed the current structures of the first wave
CCGs and their association with the local oncology networks, new commissioning
support bodies and oncology centres to assess the practicality of implementing
current patient access schemes. We also reviewed new schemes approved by the
Italian medicines agency, AIFA, to accelerate reimbursement for new drugs espe-
cially when there is limited availability at launch. RESULTS: It is clear that the
suggested circa 200 proposed CCGs will have limited resources to fund suitable
management structures to run risk share/patient access scheme effectively. Spend
on pharmaceuticals, especially with public and physician demand, for innovative
premium cost cancer treatments, will now be led and influenced by General Prac-
titioners (GPs). The critical question facing family GPs will be how can they address
the funding of these high cost treatments yet still satisfy patient demand. One
approach that could be adopted to a new type of patient access scheme is now
being lead by AIFA who have developed an approach to enhance the reimburse-
ment potential of innovative anti-cancer medicines. CONCLUSIONS: The new
commissioning support bodies recently appointed by the English Department of
Health’s, National Commissioning Board, could easily follow the Italian suggested
approach; to help provide decision-making GPs with a framework to assess new
premium prices medicines, outside of the current support provided by NICE and
the Patient Access Scheme Liaison Unit.
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BEYOND THE EVIDENCE - THE INFLUENCE OF DECISION PROCESSES ON
OUTCOMES IN COVERAGE DETERMINATION OF HEALTH TECHNOLOGIES
Fischer KE1, Rogowski WH2, Leidl R2, Stollenwerk B2
1University of Hamburg, Hamburg, Germany, 2Helmholtz Zentrum München - German Research
Center for Environmental Health, Neuherberg, Germany
OBJECTIVES: Coverage decision processes determine the accessibility of health
technologies. Cost-effectiveness considerations have been identified to explain
decision outcomes. Beyond the evidence, outcomes may be influenced by the pro-
cess configurations used by decison makers. The aim of this exploratory study was
to analyse the influences of transparency, stakeholder participation, scientific
rigour of assessment and evidence judgments on decision outcomes in coverage
decision-making. METHODS: Using survey data of 77 decisions from 13 countries,
we examined whether outcomes differ by 14 variables that describe components of
coverage decision-making and the technology considered for coverage. Neglecting
the level of reimbursement, we analysed the likelihood of committees to cover a
technology, i.e. positive (including partial coverage) vs. negative coverage deci-
sions. We performed non-parametric univariate statistical tests and binomial lo-
gistic regression. To identify influences on decision outcomes, we applied a step-
wise variable selection procedure. RESULTS: We identified associations between
the decision outcome and the following variables: the technology is a prescribed
medicine (p0.0097); the health condition is an endocrine, nutritional or metabolic
disease (p0.0311) and the judgment of the evidence after assessment (p0.0001).
The first estimation of the logistic regression model suggested a quasi-complete
separation for those decisions where effectiveness and costs/cost-effectiveness
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were clearly judged favourable or unfavourable. In decisions where the evidence
was rated uncertain or was not assessed, we found that the number of stakeholders
participating in the voting stage (odds ratio2.52; p0.03) and the scientific rigour
in assessment of costs/cost-effectiveness (OR6.25; p0.06) increased the likeli-
hood of a positive decision outcome. On the contrary, it significantly decreased for
prescribed medicines (OR0.05; p0.003). CONCLUSIONS: Despite claims for mak-
ing transparent and participative coverage decisions, the phase of evidence gener-
ation and synthesis is most critical for technology appraisal. Decison makers usu-
ally adapt the assessment recommendations. Decision outcomes seem to a large
extent independent of how processes are configured.
PODIUM SESSION III:
VACCINE RESEARCH
VA1
A EUROPEAN-WIDE STUDY ON THE ROLE OF STREPTOCOCCUS PNEUMONIAE
IN COMMUNITY-ACQUIRED PNEUMONIA AMONG ADULTS: A META-ANALYSIS
Pechlivanoglou P1, Rozenbaum M1, van der Werf T2, Lo-Ten-Foe J2, Postma M1, Hak E1
1University of Groningen, Groningen, The Netherlands, 2University Medical Center Groningen,
Groningen, The Netherlands
OBJECTIVES: Community-acquired pneumococcal pneumonia is an important
cause of hospitalization and death among adults, but figures on the prevalence of
Streptococcus pneumoniae largely vary. We aimed to identify the prevalence of Strep-
tococcus pneumoniae by systematically reviewing all available etiological studies of
adult patients with community-acquired pneumonia (CAP) over the period January
1990- November 2011 across European countries. METHODS: Two reviewers con-
ducted a systematic literature search using PubMed of English-language articles on
the prevalence of adult CAP caused by S. Pneumoniae and manually reviewed the
article bibliographies. A mixed-effects meta-regression model was developed and
populated with 24,236 patients obtained from 79 articles that met in- and exclusion
criteria. The meta-regression was adjusted for country and region characteristics
as well as other possible independent covariates. RESULTS: The findings from the
mixed-effects meta-regression model indicate that the observed prevalence of S.
pneumoniae in CAP significantly differs between European regions even after ad-
justing for various covariates including patient characteristics, diagnostic tests,
antibiotic resistance and health-care setting. Performing a diagnostic PCR assay
increased the probability of detecting S. pneumoniae substantially, compared to all
other diagnostic tests included. Furthermore, S. pneumoniae was more likely to be
confirmed as the cause of a CAP in cases treated in the ICU as compared to those
treated in the hospital or in the community. CONCLUSIONS: This study provides
estimates of the prevalence of S. Pneumoniae in CAP, independent of study design,
or other risk factors, which could be used for predictions of the health and eco-
nomic impact of adult pneumococcal vaccination.
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CORRELATES OF PROTECTION FOR VACCINES: WHEN DOES A CORRELATE
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Desai K1, Chen X2, Bailleux F3, Qin L4, Dunning A5
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OBJECTIVE: A fundamental information needed to conduct economic evaluations
of vaccines is effectiveness against disease. However, effectiveness is not always
observed directly and relies on an immunological response that predicts protec-
tion. Typical immune responses which are predictive of protection are neutralizing
antibodies, called surrogates or correlates of protection (COP). Often the COP is
reduced to a threshold value that differentiates between protected and susceptible.
COPs are relied on in place of estimates of effectiveness and for immunization
policy, however there are no consistent criteria or statistical methods for establish-
ing candidate immune response as predictive COP. Our aims were to review pro-
posed hierarchies of evidence necessary to establish a COP and statistical methods
used to relate immune responses to protection. METHODS: The strength of evi-
dence for demonstrating a COP based on different frameworks and early and mod-
ern statistical methods approaches to establish a COP were reviewed. Findings and
Recommendations: Different frameworks define different levels of confidence in
COPs. The Prentice framework is significance testing-driven and requires protec-
tion to be related to vaccination, the correlate related to the vaccine and correlate
related to clinical endpoint. Moreover vaccination should not add additional infor-
mation on protection over that explained by the correlate. A framework by Qin
proposes levels of evidence based on single or multiple randomized trials. To esti-
mate thresholds, early vaccine studies relied on inspection of disease rates ob-
served in discrete intervals of assay values. Modern examples employed Chang-
Kohberger method, but this requires an estimate of vaccine efficacy based on
occurrence of disease before it can be used. The scaled-logit model permits esti-
mation of continuous protection curves by antibody titer. In addition to statistical
criteria, other considerations include clear endpoint definition, laboratory assays,
host and population factors. New statistical methods should be developed and
tested within evidence frameworks to better obtain estimates of vaccine effective-
ness.
VA3
HOW AGENT-BASED MODELS REVEAL THE DYNAMIC OF EPIDEMICS – A CASE
STUDY ON INFLUENZA
Miksch F1, Urach C1, Zauner G2, Schiller-Frühwirth I3, Endel G3, Einzinger P2, Popper N2
1Vienna University of Technology, Vienna, Austria, 2Dwh Simulation Services, Vienna, Austria,
3Main Association of Austrian Social Security Institutions, Vienna, Austria
OBJECTIVES: Influenza is a disease that occurs every year for a few months in
winter season. Predictions on vaccination strategies require a deep understanding
of current influenza epidemics. The aim of this work is the reproduction of a past
influenza season through a model, its examination and to make its dynamics
transparent. METHODS: We used an agent based epidemic model to simulate the
spread of influenza. It belongs to the class of dynamic transmission models and
simulates single persons with individual behavior who live in an environment,
meet each other and spread the virus from person to person upon contacts. Con-
tacts are based on statistical data and social studies; epidemiological parameters
are found in clinical studies and through calibration. RESULTS: Estimates say that
about 5% of the population fall sick with influenza every year in Austria. The model
shows clearly that this number is highly implausible under naive assumptions
because the epidemic would not behave like this; instead it would be much stron-
ger or die out – depending on the parameters. This reveals that our knowledge on
influenza is insufficient. Three additional assumptions might solve the problem:
First, that the influenza season highly depends on the seasonal climate, second,
that many people are generally resistant for the whole season and third, that many
people undergo infections without symptoms. Simulation of these assumptions
reveal three different possible propagations of the influenza that all result in 5%
sick people. CONCLUSIONS: The model cannot answer all questions about influ-
enza. But it is able to show clearly where we need more information and it provides
the possibility to test different assumptions and evaluate them. In other words, the
model can lead to a deeper understanding of the real world by examining assump-
tions that could not be observed directly so far.
VA4
FOUND THE MISSING LINK? HOW TO RELATE COHORT MODELS TO OBSERVED
POPULATION DATA
Standaert B1, Ethgen O2, Emerson RA3
1GlaxoSmithKline Vaccines, Wavre, -, Belgium, 2University of Liege, Liege, Belgium, 3Emerson
Consulting, Tervuren, Belgium
OBJECTVES: Pre-launch economic models are constructed to simulate long-term
changes in costs and effects. Typically Markov cohort models are used, whereas the
input often available to parameterize the models is obtained from cross-sectional,
annual, population data. The question is how to make the link and reconcile results
from long-term cohort models with annual observed population data? An illustra-
tion is given with modelled and observed hospitalisations due to rotavirus related
acute gastroenteritis. METHODS: The spread of hospitalisations of children up to
the age of 5 years, observed over a one -year period follows a normal distribution
(seasonality of the infection) with a peak around February March each year. The
assessment is done by 1-year age-groups (0 to 1y; 1 to 2y; 2 to 3y; 3 to 4y; 4 to 5y). The
parameters of this normal distribution are used to construct an overall modelled
population density curve with the same annual spread. Within this construction
the weekly spread of hospitalisations by age follows the density curve of the cohort
model with an age-specific Weibull distribution. To compare the model results
with the observation we analyse the age-group spread of hospitalisations but also
the results following the introduction of a specific intervention such as
vaccination. RESULTS: Pre-vaccination, the fit of the age-related spread of hospi-
talisations modelled using the population model to the observed data was compel-
ling (regression-scale model fit  0.05). Post-vaccination the modelled and ob-
served reduction in hospitalisations matched, however in the unvaccinated older
children the model predicted a lower reduction than observed which could be
explained by a herd protection effect in the observed population (indirect vaccine
benefit). Herd protection was not captured in the static model. CONCLUSIONS: It is
possible to make the link between cohort models and observed population data
provided the underlying model characteristics reflect reality.
RESEARCH POSTER PRESENTATIONS – SESSION I
HEALTH CARE USE & POLICY STUDIES
HEALTH CARE USE & POLICY STUDIES - Consumer Role In Health Care
PHP1
INCORPORATING THE PATIENT’S VOICE INTO THE ASSESSMENT OF MEDICAL
DEVICES: A COMPARISON OF THE UNITED STATES AND EUROPE
Doward L1, Whalley D2, Houghton K2, DeMuro C3, Evans E3, Gnanasakthy A4
1RTI Health Solutions, Manchester, Manchester, UK, 2RTI Health Solutions, Manchester, UK, 3RTI
Health Solutions, Research Triangle Park, NC, USA, 4Novartis Pharmaceuticals Corporation, East
Hanover, NJ, USA
OBJECTIVES: Medical devices (MDs) play a major role in many aspects of health
care. The United States (US) and Europe (EU) categorise MDs into different classes,
with greatest regulatory control imposed on the highest risk Class III devices. In the
US, the Food and Drug Administration (FDA) approves Class-III MDs. In EU, the
European Commission sets the regulatory framework through which ‘notified bod-
ies’ confer a Confomité Européene (CE) mark for MDs. The purpose of this study
was to evaluate the extent to which patient-reported outcomes (PROs) are consid-
ered in the assessment of Class-III MDs in the US and EU. METHODS: The Drug
Approval Packages of MDs granted approval by the FDA from 2006-2011 were re-
viewed to identify MDs presenting PRO-related data. Ophthalmology MDs were
reviewed in greater detail to explore the range of PRO constructs presented. No
publically available database of EU MD approvals exists, making a parallel search
impossible. Instead, clinical trial databases (e.g. ClinicalTrials.gov) were searched
to identify EU-registered trials with PRO-endpoints for the ophthalmology MDs
identified from the US FDA review. RESULTS: The FDA approved 197 MDs from
2006-2011, of which 52(26.4%) presented PRO data. PRO-claims were lowest in 2008
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